New research indicates that certain anti-cancer therapies may hasten cellular aging, where changes in the DNA of patients may contribute
Continue reading »
Home »
Bladder Cancer Indication Withdrawn for Durvalumab
After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be
Continue reading »
Immunotherapy: The Future of Lung Cancer Treatment?
Lung cancer is one of the most common types of cancer worldwide and accounts for around one fifth of cancer-related
Continue reading »
Treatment of Candidiasis (Thrush)
Candida infection is a fungal infection. It is often easy to treat and symptoms resolve with the use of antifungal
Continue reading »
Emend IV
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. EMEND® IV Fosaprepitant dimeglumine Consumer Medicine Information
Continue reading »
Letrozole Sandoz
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. LETROZOLE SANDOZ® Letrozole film-coated tablets Consumer Medicine
Continue reading »
Opdivo
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. OPDIVO CMI _V17.0 (op-DEE-voh) Nivolumab (nee-vol-u-mab) Consumer
Continue reading »
De-escalating breast cancer therapy—can some patients be spared chemotherapy?
About one of every five breast cancers presents with high levels of HER2 proteins. Known as HER2-positive breast cancer, these
Continue reading »
Cancer FAQ – The seven most important questions and answers
About four million Germans are suffering in their lives already to cancer (as of 2017). For 2018, the cancer information
Continue reading »
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy
FRIDAY, Dec. 14, 2018 — Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism
Continue reading »